Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis–Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen - HOST-ASSURE

Description:

Subgroup analysis of the CURRENT-OASIS 7 trial demonstrated that a maintenance daily dose of 150 mg of clopidogrel for 1 week was associated with superior outcomes at 1 month, as compared with 75 mg daily in patients undergoing drug-eluting stent (DES) percutaneous coronary intervention (PCI). The current trial sought to compare outcomes at 1 month in Korean patients receiving triple therapy with aspirin, clopidogrel 75 mg daily, and cilostazol versus dual therapy with aspirin and clopidogrel...